Pfizer Inc. has agreed to purchase International Blood Therapeutics Inc. for $5.4 billion, in a deal that will give the large drugmaker a foothold within the remedy of sickle-cell illness.
Pfizer mentioned Monday it might pay $68.50 a share in money for International Blood Therapeutics, which has one of many few authorized therapies for sickle-cell illness. The Wall Road Journal reported Friday that the companies were in advanced talks.
